| 1-1 1-2 1-3 1-4 1-5 1-6 | By: Menéndez, Campbell (In the Senate - Filed March 12, 2021; April 1, 2021, read first time and referred to Committee on Business & Commerce; May 5, 2021, reported adversely, with favorable Committee Substitute by the following vote: Yeas 7, Nays 0; May 5, 2021, sent to printer.) |
|--|---|
| 1-7 | COMMITTEE VOTE |
| 1-8 | Yea Nay Absent PNV |
| 1-9 | Hancock X |
| 1-10 | Nichols X |
| 1 - 11 1 - 12 | Campbell X Creighton X |
| 1-12 | Creighton X Johnson X |
| 1-13 | Menéndez X |
| 1-14 | Paxton X |
| 1-16 | Schwertner X |
| 1-17 | Whitmire X |
| 1 - 18 1 - 19 | COMMITTEE SUBSTITUTE FOR S.B. No. 2051 By: Hancock A BILL TO BE ENTITLED |
| 1-20 | AN ACT |
| $ \begin{array}{c} 1-21\\ 1-22\\ 1-23\\ 1-24\\ 1-25\\ 1-26\\ 1-27\\ 1-28\\ 1-29\\ 1-30\\ 1-31\\ 1-32\\ 1-33\\ 1-34\\ 1-35\\ 1-36\\ 1-37\\ 1-38\\ 1-39\\ 1-40\\ \end{array} $ | <pre>relating to step therapy protocols required by health benefit plans for coverage of prescription drugs for serious mental illnesses. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. Subchapter B, Chapter 1369, Insurance Code, is amended by adding Section 1369.0547 to read as follows: <u>Sec. 1369.0547. STEP THERAPY PROTOCOLS FOR PRESCRIPTION</u> DRUGS TO TREAT SERIOUS MENTAL ILLNESSES. (a) In this section, "serious mental illness" has the meaning assigned by Section <u>1355.001.</u> (b) This section applies only to a drug prescribed to an enrollee who is 18 years of age or older to treat a diagnosis of a serious mental illness. (c) A health benefit plan that provides coverage for prescription drugs to treat a serious mental illness may not require, before the health benefit plan provides coverage of a prescription drug approved by the United States Food and Drug Administration, that the enrollee: (1) fail to successfully respond to more than one different drug for each drug prescribed, excluding the generic or pharmaceutical equivalent of the prescribed drug; or</pre> |
| 1-40 | (2) prove a history of failure of more than one |
| 1-41 | different drug for each drug prescribed, excluding the generic or |
| 1-43 | pharmaceutical equivalent of the prescribed drug. |
| 1-44 | (d) Subject to Section 1369.0546, a health benefit plan |
| 1-45 | issuer may implement a step therapy protocol to require a trial of a |
| 1-46 | generic or pharmaceutical equivalent of a prescribed prescription |
| 1-47 | drug as a condition of continued coverage of the prescribed drug |
| 1-48 | <u>only:</u> |
| 1-49 | (1) once in a plan year; and |
| 1-50 | (2) if the equivalent drug is added to the plan's drug |
| 1-51 | formulary. |
| 1-52 | SECTION 2. This Act applies only to a health benefit plan |
| 1 - 53 1 - 54 | delivered, issued for delivery, or renewed on or after January 1, 2022. A health benefit plan delivered, issued for delivery, or |
| 1-54 1 - 55 | renewed before January 1, 2022, is governed by the law as it existed |
| 1-56 | immediately before the effective date of this Act, and that law is |
| 1-57 | continued in effect for that purpose. |
| 1-58 | SECTION 3. This Act takes effect September 1, 2021. |
| 1-59 | * * * * * |

1-59